Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...
Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological ...
The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ...
Science Reports of the Tokyo Kyoiku Daigaku, Section A, Vol. 9, No. 220/231 (January 20, 1968), pp. 218-235 (18 pages) ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about ...
If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a tech-enabled biopharma company combining automated, experimental biology with artificial intelligence to discover novel treatments that extend beyond our ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback